Literature DB >> 24331818

Burden of human papillomavirus infections and related diseases in the extended Middle East and North Africa region.

Salvatore Vaccarella1, Laia Bruni2, Muhieddine Seoud3.   

Abstract

In this chapter, we present the available information on the burden of human papillomavirus (HPV)-related cancers (cancers of the cervix, anogenital cancers, and cancers of the oral cavity and pharynx), as well as available data on the prevalence and distribution of HPV types in women with and without cervical cancer, for the countries of the Extended Middle East and North Africa region (EMENA). The EMENA region is characterized by societies that share similar cultures and religions and that are considered to have a more conservative sexual behaviour compared to Western societies. The incidence of cervical cancer is estimated to be relatively low, although it is difficult to assess precisely because systematic and national cancer registries are lacking in many countries of the EMENA region. In these countries, nationwide programs of cervical cancer screening do not exist or are based on a limited opportunistic cytology-based screening, which often lacks quality assurance. The incidence of anogenital cancers other than cervix is very low. The incidence of cancers of the oral cavity and pharynx is relatively high in some countries, particularly in Pakistan. Relatively low levels of HPV prevalence have been observed in the several surveys conducted in the EMENA region, although only few young women were included in these studies. Possible changes in lifestyle and sexual behaviour in younger generations might, however, change this scenario. Thus, improving the information on the burden of HPV-related cancers and on the HPV prevalence in the general population is essential to develop a comprehensive intervention policy for future management of cervical cancer in this area. This article forms part of a regional report entitled "Comprehensive Control of HPV Infections and Related Diseases in the Extended Middle East and North Africa Region" Vaccine Volume 31, Supplement 6, 2013. Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer registry; Cervical cancer incidence; Extended Middle East and North Africa; HPV prevalence; HPV-related cancers

Mesh:

Year:  2013        PMID: 24331818     DOI: 10.1016/j.vaccine.2012.06.098

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Oral and Oropharyngeal Cancers and Possible Risk Factors Across Gulf Cooperation Council Countries: A Systematic Review.

Authors:  Wedad Saeed Alqahtani; Nawaf Abdulrahman Almufareh; Halah A Al-Johani; Rasil Khaled Alotaibi; Consul Iworikumo Juliana; Nada Hamad Aljarba; Abdulqader Saeed Alqahtani; Bandary Almarshedy; Abdelbaset Mohamed Elasbali; Hussain Gadelkarim Ahmed; Bassam Ahmed Almutlaq
Journal:  World J Oncol       Date:  2020-08-10

2.  Burden of Cervical Cancer in the Eastern Mediterranean Region During the Years 2000 and 2017: Retrospective Data Analysis of the Global Burden of Disease Study.

Authors:  Fereshteh Safaeian; Shidrokh Ghaemimood; Ziad El-Khatib; Sahba Enayati; Roksana Mirkazemi; Bruce Reeder
Journal:  JMIR Public Health Surveill       Date:  2021-05-12

Review 3.  Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis.

Authors:  Rebecca Kemunto Ogembo; Philimon Nyakauru Gona; Alaina J Seymour; Henry Soo-Min Park; Paul A Bain; Louise Maranda; Javier Gordon Ogembo
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

4.  Molecular epidemiology and genotype distribution of Human Papillomavirus (HPV) among Arab women in the State of Qatar.

Authors:  Devendra Bansal; Asha A Elmi; Sini Skariah; Pascale Haddad; Laith J Abu-Raddad; Aysha H Al Hamadi; Nady Mohamed-Nady; Nahla M Affifi; Randa Ghedira; Elham Hassen; Asma A J Al-Thani; Afaf A H M Al-Ansari; Ali A Sultan
Journal:  J Transl Med       Date:  2014-11-26       Impact factor: 5.531

5.  Frequency of Human Papillumavirus among Women with High-Grade Squamous Intraepithelial Lesions and Invasive Cervical Cancer Attending Shahid Beheshti University of Medical Sciences Clinics, Tehran, Iran.

Authors:  Nahid Khodakarami; Afshin Moradi; Hamidreza Mirzaei; Farah Farzaneh; Parvin Yavari; Mohamad Esmaeil Akbari
Journal:  Iran J Public Health       Date:  2014-11       Impact factor: 1.429

6.  Human Papillomavirus (HPV) Infection: Molecular Epidemiology, Genotyping, Seroprevalence and Associated Risk Factors among Arab Women in Qatar.

Authors:  Asha A Elmi; Devendra Bansal; Anushree Acharya; Sini Skariah; Soha R Dargham; Laith J Abu-Raddad; Nady Mohamed-Nady; Paul Amuna; Asma A J Al-Thani; Ali A Sultan
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

7.  Reduced rate of human papillomavirus infection and genetic overtransmission of TP53 72C polymorphic variant lower cervical cancer incidence.

Authors:  Ghazi A Alsbeih; Najla M Al-Harbi; Sara S Bin Judia; Hatim A Khoja; Mohamed M Shoukri; Asma M Tulbah
Journal:  Cancer       Date:  2017-04-10       Impact factor: 6.860

8.  Awareness and knowledge about cervical cancer prevention methods among Tunisian women.

Authors:  R Gamaoun
Journal:  J Prev Med Hyg       Date:  2018-03-30

9.  Prevalence and genotyping of high risk human papillomavirus in cervical cancer samples from Punjab, Pakistan.

Authors:  Abida Siddiqa; Maidah Zainab; Ishtiaq Qadri; Muhammad Faraz Bhatti; Joanna L Parish
Journal:  Viruses       Date:  2014-07-17       Impact factor: 5.048

Review 10.  A review of the infection-associated cancers in North African countries.

Authors:  Wafaa Mohamed Hussein; Wagida A Anwar; Mohammed Attaleb; Loubna Mazini; Asta Försti; Roxana-Delia Trimbitas; Meriem Khyatti
Journal:  Infect Agent Cancer       Date:  2016-08-10       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.